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Abstract 
 
 
The Opioid Crisis is of significant public health relevance, as more than 2 million 
Americans suffer from opioid use. The State of Pennsylvania Human and Health Services (HHS) 
Department offered an opportunity for hospitals to participate in a quality incentive program when 
treating Medicaid patients coming into the Emergency Department with opioid use disorder 
(OUD). Beginning in 2019, the program included two phases; the first phase would pay hospitals 
for implementing treatment pathways for patients in 2019, and the second phase required follow 
up care for these patients to be evaluated in 2020. Hospital System X (HSX) and its seven hospitals 
decided to be a part of this pilot program to mitigate the opioid epidemic within Pennsylvania. 
HSX successfully implemented the first phase in 2019, and is currently preparing for the second 
phase of the program. 
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1.0 Opioid Crisis 
 
 
 
Opium comes from the poppy plant, and upon consumption, can produce pain relieving 
affects (Feige & Miron, 2008). Opium is a natural opiate, whereas opioids are at least partially 
synthetic. The synthetic nature of opioids means that they can be more potent and therefore more 
addictive and dangerous to use (Recovery Centers of America, 2017). There is currently an overuse 
of opioids within the United States that can be viewed as having occurred in three separate waves.  
The first wave included the exponential number of prescriptions written to relieve pain, which was 
pushed by pharmaceutical companies anxious to sell their products. The second wave included an 
increase in heroin usage, and the third wave included movement away from heroin towards 
fentanyl when strict guidelines on prescribing opioids were implemented (Liu, Pei, & Soto, n.d.). 
The federal government approached the third wave of the opioid crisis by providing funding to each 
state, as each state grappled with appropriating this money in the optimal way to provide resources in 
its state to combat the epidemic. 
The first wave of the opioid crisis traces its origins to around 1991, when there was a push 
to treat pain as the “fifth vital sign”. The initial four vital signs for medical treatment included 
body temperature, blood pressure, pulse, and respiratory rate (Cleveland Clinic, 2019). In the mid-
1990s there was a push from the American Pain Society to add pain as the fifth vital sign. In 2000, 
The Joint Commission accepted that pain was the “fifth vital sign”, and recommended that there 
be an assessment of pain at each clinical visit. This led to physicians prescribing higher amounts 
of pain medications to their patients, backed by the reassurance of the pharmaceutical companies 
that the pain relievers were safe and non-addictive. Pharmaceutical companies capitalized on this 
new market for pain management beyond non-cancer patients (Vadivelu, Kai, Kodumudi, 
Sramcik, & Kaye, 2018). Prior to the acceptance of The Joint Commission accepting the “fifth 
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vital sign”, pain management opioid prescriptions were predominantly used to treat cancer 
patients. By 1999, more than 80% of those using prescription opioids were non-cancer patients 
(Liu, Pei, & Soto, n.d.). 
The second wave of the opioid crisis began around 2010 when oxycontin was no longer 
crushable, which prevented users from injecting the drug. As the government became stricter on 
allowing prescription opioid drugs, efforts to circumvent their use caused a higher use of heroin, 
along with the diversion of opioid drugs prescribed off label.  The government, while stemming 
one area of opioid addiction, did not provide a program for sterile syringes for those opioid users 
injecting drugs.  Programs such as providing syringes could help prevent spread of diseases, which 
were causing an increase in deaths. Heroin is relatively cheap and easy to obtain compared to other 
opioids, and additionally, leads to an increase risk for HIV/AIDS, hepatitis B and C, and skin 
infections, as heroin is commonly injected (Liu, Pei, & Soto, n.d.). 
The third wave began around 2013-2014 with an increase in deaths due to synthetic 
fentanyl. The death toll only continued to climb, with approximately 20,000 deaths relating to 
opioids occurring in 2016 (Rubin, 2017). 
Today, 2.6 million Americans suffer from opioid use disorder (OUD) (Rubin, 2017). 
“Opioid Use Disorder (OUD) is defined by the Diagnostic and Statistical Manual of Mental 
Disorders (fifth edition),1 as the maladaptive use of opioids, prescribed or illicit, resulting in two 
or more criteria that reflect impaired health or function over a 12-month period” (Connery, 2015). 
An individual’s usage of opioids does not define the disorder, but rather the impact on that 
individual’s health and mental or physical function defines OUD. 
Centers for Disease Control (CDC) and the US Government have established guidelines 
for prescribing opioids to non-cancer, palliative care, and end-of-life care patients.  The change in 
regulations by the CDC concerning who can prescribe opioids, and how often they are allowed to 
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prescribe them, has shifted; hospitals and large healthcare organizations are now measured on 
quality in regards to opioids and pain management. The Hospital Consumer Assessment of 
Healthcare Providers and Systems (HCAHPS) survey are used to help determine hospital 
reimbursements. The Centers for Medicare and Medicaid Services (CMS) declared in 2018 they 
would no longer consider questions related to pain on the HCAHPS survey when considering 
hospital reimbursements. This decision was driven by concerns that over-prescribing pain 
medications was due to a probability that hospitals would receive better survey scores by patients 
who would give favorable ratings on pain related questions. There is some controversy over 
whether there, actually, was a correlation between increased prescribing of opioids due to fear of 
not scoring well on the HCAHPS survey (Mattina, 2017).
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2.0 Opioid Treatments 
 
 
 
 
As opioid use has risen to new heights, treating OUD has become more urgent. According 
to the Substance Abuse and Mental Health Services Administration (SAMHSA) there are specific 
requirements for providers to be allowed to provide Medication Assisted Treatment (MAT) 
(Kampman & Jarvis, 2015). Only providers who have received special training to prescribe opioids (known 
as having an x-waiver) are allowed to prescribe MAT.  These providers must go through educational trainings 
and can only prescribe a limited number of opioids each year. MAT involves a combination of medications 
and therapy to help treat OUD and prevent relapses. The medications used for MAT can include 
buprenorphine, methadone, and naloxone (more in appendix). Buprenorphine and methadone can 
be administrated while the patient still has opioids in their systems. Buprenorphine is typically 
prescribed when a patient is going through opioid withdrawal, to prevent buprenorphine-
precipitated opioid withdrawal. Methadone administration is different, and the patient does not 
have to be in withdrawal to give the first dose. Methadone is usually given in a step-wise fashion 
that starts with a small dose and builds up the dosage to avoid over-sedation and overdose, because 
methadone itself is addictive (SAMHSA, n.d.). 
In a study conducted, providers who had the fewest concerns around prescribing pain 
medication to their chronic noncancer pain (CNCP) patients were the providers whose 
organizations were affiliated with opioid prescribing guidelines and had accessibility to pain 
consultations (Franklin, Fulton-Kehoe, Turner, Sullivan, & Wickizer, 2013). Opioids are 
continually being studied to determine the safest and most effective ways for prescription opioids 
to relieve pain without patients becoming addicted or misusing the medicine. The Centers for 
Disease Control (CDC) established a set of guidelines with 12 recommendations (CDC, 2019). 
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3.0 Quality Improvement Program 
 
 
 
 
The Centers for Disease Control and Prevention noted that the opioid crisis costs the United 
States economy $78.5 billion a year. This economic burden comes from lost productivity of the 
individuals with OUD, healthcare treatment costs, and criminal justice costs (National Institute on 
Drug Abuse, 2019). This economic factor was taken into account in July 2017 when the President’s 
Commission on Combating Drug Addiction and the Opioid Crisis issued a report with several 
recommendations for the government to mitigate the opioid crisis for its citizens. Money was 
allocated to be used specifically for opioid prevention and recovery methods. The federal 
government, through the Centers for Disease Control, allocated varying one-time amounts per state 
based on need (HHS Press Office, 2019). The Department of Health and Human Services (DHS) 
announced, through the Hospital and Health system Association of Pennsylvania (HAP), a quality 
incentive program aimed at targeting opioid use disorder (OUD) through hospitals’ Emergency 
Departments (CDC, 2019) [Appendix B]. The quality improvement program is a modification of 
the Healthcare Effectiveness Data and Information Set (HEDIS) program “Follow-Up After 
Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence (FUA)”. DHS 
limits the modification to include only opioid use disorder and opioid poisoning diagnoses, rather 
than all drug use, limiting the scope of their program to target only patients with OUD. HEDIS 
currently only measures the primary diagnosis on a patient’s chart, when looking at the 
claim/encounter. The DHS modification allows opioid diagnoses to be included up to the ninth 
position in the patient’s chart, which reflects in claims/encounter in billing, as an opioid poisoning.  
This is how hospitals are to be reimbursed by Medicaid for these patients [Appendix C]. 
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The incentive program is designed to allow hospitals to receive incentive payments for 
implementing one of four pathways created by the government for use in hospital Emergency 
Department ‘s (ED) for treatment of OUD for individuals with Medicaid. The goal of the program 
is to eliminate the need for repeat treatment and revisits in the ED for patients with OUD by 
assisting these individuals in receiving additional help within seven days of their care in the ED. If 
an individual who received OUD treatment returns to the ED within seven days, the DHS will 
evaluate these events separately, as another ED visit is not an acceptable follow-up within the 
seven-day period. There are two phases to the program, with the first phase called the ‘Process 
Incentive’ phase.  
The first phase was the implementation of clinical pathways in Year 1 (2019). The second 
phase was ‘Outcome Incentive’; the measurement of the effectiveness for seven-day follow-up after 
OUD treatment in the ED, to occur in Year 2 (2020). Both phases have one-time incentive payments 
attached to them [Appendix B].  
The DHS program is structured with incentive payments distributed in 2019-the amount 
allocated totaling $30 million across all participating hospitals. An additional $5 million dollars 
was allocated for benchmark and incremental payments that are to be made in 2020 for 
performance related to seven-day follow up care. In total, the program amounts to $35 million in 
payments towards helping patients with OUD [Appendix B]. Participating hospitals were classified 
by Community HealthChoices (CHC) members (Pennsylvania’s managed care program for dually-
eligible Medicare and Medicaid patients) seen in the ED for OUD. Hospitals were divided into one 
of three tiers based on their patient volume in the ED relating to OUD,  and trending performance 
data from the Calendar Year 2016. 
a. “Tier 1: Low-Volume EDs – Hospitals that had less than 20 OUD ED visits must have a 
minimum of 1 HealthChoices recipient. 
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b. Tier 2: Standard EDs – Hospitals that had between 20 and 200 OUD ED visits must have 
a minimum of 10 HealthChoices recipients. 
c. Tier 3: High Volume EDs - Hospitals that had more than 200 OUD ED visits must have 
a minimum of 20 HealthChoices recipients.” [Appendix B] 
The program was set up so that the hospitals had to meet four requirements to be considered 
eligible to receive the incentive payments. Each hospital system had the opportunity to do this with 
all of their hospitals on a hospital by hospital basis. 
1. Each of the pathways utilized had to be defined in writing by September 28, 2018, and 
the minimum HealthChoices recipients reached by January 17, 2019. 
2. Care management teams had to be operationalized, with 24 hours coverage, and ED 
personal trained on OUD guidelines of care, stigma, medicated-assisted treatment (MAT). 
3. Hospitals had to attest to these requirements by a deadline of November 30, 2018. 
4.Hospitals had to submit electronic continuity of care documents (CCDs) to the 
Department for Medicaid recipients by July 1, 2019, or prove that they were in the process of 
working toward this goal. 
 Along with meeting the requirements listed above in the 2019 year, participating and eligible 
hospitals could be paid for implementing clinical pathways; for treatments of  patients with OUD. 
There are four pathways which hospitals could implement, with implementation of each pathway 
giving the hospitals a chance to earn more money. The implementation of the clinical pathways is 
used to help treat patients with OUD coming into the Emergency Department, improve the seven-
day follow-up care, and reduce variability of care being provided across the state. Implementation 
of each of the pathways is valued with increasing payouts with the more pathways initiated. The 
base payment of $25,000 would be awarded for one pathway. Implementation of the second, third, 
and fourth pathways are as follows: $37,000 – 2nd, $56,00 – 3rd, and $75,000 – 4th. The clinical 
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pathways that could be implemented by the hospitals for payment are as follows: 
1. “ED initiation of buprenorphine1 with warm hand off to the community; 
 
2. Direct warm hand off to the community for MAT2 or abstinence based treatment; 
3.Specialized protocol to address pregnant women with OUD; and 
4.Direct inpatient admission pathway for methadone or observation for buprenorphine 
induction.” [Appendix B] 
Hospitals who implemented all four pathways would receive a one-time payment of 
 
$193,000, and potentially more, which would be dependent upon whether other hospitals 
participating in the HAP program in the state of Pennsylvania were able to implement all four 
clinical pathways. Remaining funds, after the competition of pathway payments, were divided 
among the hospitals who implemented all four clinical pathways [Appendix B].
                                                     
1 Buprenorphine is a medication commonly prescribed to OUD patients. It is a partial opioid agonist meaning it binds to the same mu-receptor in the 
nervous system that opioids bind helping to relieve withdrawal symptoms (Information, Pike, MD, & Usa, 2009).   
2 Medication Assisted Treatment (MAT), involves a combination of medications and therapy to help treat OUD, and prevent relapse (Kampman & Jarvis, 
2015).  
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4.0 Implementation 
 
 
 
 
Hospital System X (HSX) was made aware of this program through HAP, of which they 
are a member, applied to participate in the program in 2018, and was deemed eligible to participate 
by the state. Participating in the program was a decision agreed upon by the CEO, and CQO of the 
System, with approval to move forward by the board. The project is led by the Vice President of 
Quality and Safety for the System, the chair of HSX’s Emergency Services Institute, as well as by 
Addiction Medicine. Additional key stakeholders for this project include departments such as 
regulatory, case management, strategy, and nursing education. Other key stakeholders may be 
found in Appendix D. 
HSX has seven hospitals, all of which hospitals were placed into tiers based on their 
Calendar Year (CY) 2016 and CY 2017 claims data and volume of Health Choice recipients. None 
of the seven hospitals fell into Tier 1. The hospitals that fell into Tier 2 include Hospital X1, X2, 
and X3. The other 4 hospitals; Hospitals X4, X5, X6, and X7 all fell into Tier 3. 
HSX decided to participate in the program for a myriad of reasons. The first and foremost 
was the alignment of the program with their vision of embracing health, while following through 
on their values to provide innovative and excellent patient care to help improve the health of the 
communities they serve. Additionally, HSX wished to provide better care, better health, create the 
foundation for more resilient systems, and for the obvious financial incentives advertised by the 
state. By participating in the OUD program, HSX is helping to provide the highest quality of care 
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to every patient, and improve the well-being of every patient served to form a healthier community. 
The program provided an opportunity to collaborate with the state, and other organizations within 
the state of Pennsylvania, to design the best methods of treatment. 
At the start of the project, the first steps taken by HSX were to develop a project charter, 
identify sponsors and key stakeholders, create work streams/teams, set meetings, and review cases 
and outliers with ED staff. Once these sponsors were identified, three work streams were created; 
education, technology assistance, and reporting capabilities. Next, trainings sessions were dispersed 
among nurses, social workers, and physicians regarding the definition of opioid use disorder, how 
to treat it, and how to stay unbiased and non-judgmental towards these patients. The latter was an 
attempt to make the OUD patient feel comfortable receiving treatment, and be willing to accept 
the help of hospitals in their overall treatment. Training was divided into three different training 
videos; one specifically for nurses, another for social workers, and the third for physicians. This 
was done because these healthcare employees perform different roles when interacting with 
patients with OUD. These trainings aids were the first step in the process, with knowledge and 
foresight that policies would need to be updated, and there must eventually be a simplification and 
standardization of parts of the processes that would allow for a more system oriented process. This 
would ensure the system is more effectively and efficiently able to capture patients who enter the 
EDs with OUD, and ensuring that the patients make it to follow up treatments.  
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5.0 Outcomes and Limitations 
 
 
 
 
HSX has completed Year 1; the process initiative phase. They received the maximum 
money for implementing all four pathways. They also received additional payments from the 
residual funds remaining in the program, as not all of the potentially eligible hospitals within 
Pennsylvania operationalized their pathways last year. The amount HSX received across their 
seven hospitals totaled $2,013,177 for the successful implementation of all the pathways. 
Year 2 started in 2020, during which hospitals will be assessed based on whether or not 
patients with OUD received follow up care within seven days of discharge from the ED. 
Participating EDs, including HSX, are tasked with figuring out best ways to provide follow up care 
within the required seven days for their patients with OUD, using different models suggested from 
HAP. The process is ongoing, and while HSX currently has a model in place, there is still 
additional strategy occurring to discover the most sustainable model for follow-up care within the 
region. HSX has an effective process in place for follow up care for a large majority of their 
patients, but the patients with OUD for which the grant is giving money to hospitals, are Medicaid 
patients. These patients may or may not have any family members to help them, may not have a 
regular primary care physician, and may struggle to get to any scheduled follow up because of 
transportation issues. These patients need follow up care more acutely, but are not receiving it 
because of their extenuating circumstances, which can cause higher rates of opioid relapses. HSX 
has taken this into account when considering the best way to help solve this problem. HSX has 
strategies under consideration to best provide this follow up treatment. These strategies include 
partnering with certain collaborative sites within the surrounding areas of the hospitals, which are 
easier for OUD patients to reach, increasing behavioral and addiction medicine specialists within 
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the hospitals to help care for these patients upon their discharge, and contracting with insurance 
companies in the Medicaid sector whose members are coming to the EDs. The insurance 
companies want their patients to be healthier, thus reducing their costs. The insurance companies 
thus, typically, have an identifier of their higher risk patients, and their own initiatives to help those 
patients receive care. In this case, ensuring that their members, who are patients with OUD, stay 
out of the hospital with effective treatment the first time, before they leave the hospital. These 
measures are meant to help patients follow up with treatment within a week of their discharge. All 
of these plans have limitations that require further consideration before moving forward into 
implementation. 
There are certain guidelines that providers must follow when prescribing MAT treatment 
because the drugs aforementioned can be almost, if not just as dangerous, as opiates themselves. 
The United States Government, under the Certification of Opioid Treatment programs, 42 Code 
of Federal Regulations (CFR) 8; has created regulations such that only SAMHSA-certified Opioid 
Treatment Programs (OTPs) have the ability to prescribe methadone (Young, 2015). 
Buprenorphine can only be prescribed by providers, including physicians, nurse practitioners 
(NPs), and physician assistants (PAs), who are waiver certified (SAMHSA, n.d.). The 
requirements to become waiver certified differ by the type of provider, and are capped after a certain 
number of prescriptions have been prescribed. Without a waiver, a physician in the Emergency 
Department can only dispense three days of buprenorphine (one per day, up to three days for the 
same patient), and require patients to come back each day. A few organizations offer free training 
needed to become a waivered provider. Provider requirements for obtaining a waiver are as 
follows: a physician must complete eight hours of continuing education, while NPs and PAs must 
complete 24 hours of training to become waivered. The first year a provider is certified to prescribe 
buprenorphine they may only prescribe a maximum of 30. After holding a waiver for a full year, 
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the provider can apply to prescribe more. If approved, they may move from 30 to 100 prescriptions 
for the year. After a year of holding a maximum limit of 100 prescriptions, the provider can again 
apply for an increase in prescriptions they are allowed to prescribe, moving from 100 to 275. 
Providers are capped at 275 prescriptions for the year, no matter how long they have been waivered 
(PCSS, n.d.). 
An additional challenge HSX faced in Year 1 along with the other hospitals participating 
in the grant, was trying to submit electronic continuity of care documents (CCDs) by the original 
date specified by DHS. HSX was granted an extension while they worked on partnering with a 
Health Information Exchange (HIE) to send the necessary CCDs to the state. It was noted that 
many of the hospitals struggled with the same issues with the CCDs, and joining a HIE. 
Additionally, they needed to find the best way to provide follow up care within a week of discharge 
from the ED. HAP took this into account and has been helping Pennsylvania hospitals keep on track, 
by creating the Opioid Learning Action Network (LAN), to help reduce the costs for learning and 
implementation of resources. LAN hosts webinars periodically to encourage sharing best methods 
for implementation throughout this process. These are chances for hospitals to listen in and learn 
how to most effectively implement the steps of the quality incentive program [Appendix E]. 
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6.0 Principle to Practice 
 
 
 
 
The author was assigned the task of project manager soon after on boarding as administrative 
resident for Hospital System X, reporting to the Vice President of Quality and Safety. At this time, 
HSX had already applied for the grant and the hospitals were placed into tiers based on previous 
calendar year emergency department data. She observed meetings at first, then her role evolved into 
the opportunity to help facilitate meetings, deciding when to pull in content experts or when to 
schedule branched meetings with certain individuals. These could, and did, include the IT and data 
team, an additional medicine team, and leaders at the respective hospital EDs. The team provided 
their thoughts and options on where and how the scope of the project was progressing. It has been 
the resident’s job to help pull in the right resources and the right people to keep the project moving 
forward. There was the opportunity to reach out to community centers surrounding the hospitals 
for help in getting patients to follow up treatment, as well as reaching out to Medicaid health plans 
to help set up a system for them to connect in real time with their members, so they can assist with 
patient  follow up care. The most unbelievable part of the entire project was seeing how dedicated 
and passionate all the individuals, from the internal team to any external members with whom she 
spoke, were about helping members within the broader community with OUD receive treatment 
which could help them on the road to recovery. Having this enthusiastic response was one less 
barrier to face, as everyone encountered was eager to help in any way they could to help move the 
project forward. 
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7.0 Conclusion 
 
 
 
 
Participating in the Department of Human Services quality incentive program has allowed 
Hospital System X the opportunity to implement a design to help treat patients with opioid use 
disorder in a more effective manner to help prevent relapses, in a relatively risk free environment. 
By participating in this program, HSX was paid for implementing best practices. The hope is that 
by designing a system that can effectively help patients with OUD who have Medicaid, it will stand 
beyond the conclusion of the program and be implemented for all patients who are treated in the 
ED with OUD, whether they are insured or uninsured. This is an exciting step in the right direction, 
and if successful in western Pennsylvania, can hopefully be scaled nationwide. 
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Appendix A History of Opioids 
 
 
 
 
What are Opioids? 
 
Opium comes from the poppy plant, which is native to Turkey. The plant’s flower contains 
seeds, that when consumed release morphine and other alkaloids that can produce pain relieving 
affects (Feige & Miron, 2008). Opium is a natural opiate, whereas opioids are at least partially 
synthetic, although, these terms are used interchangeably today. The synthetic nature of opioids 
means that they can be more potent and therefore more addictive and dangerous to use. Common 
opiates include opium, morphine, and codeine, all of which come directly from the poppy plant. 
Common opioids that are produced include oxycontin, heroin, hydrocodone, and fentanyl (Opiate 
Detox Centers, 2017). 
Opiates have a long history of causing addiction. Becoming addicted to opiates may be a 
relatively new problem for the United States, but China has dealt with more than its own share of 
opiate addiction over a very long period of time, The eventually were able to solve their own opioid 
crisis. Although China’s opium crisis was different in nature than the opioid crisis of today in the 
United States, both cultures have experienced the negative effects opiates can have on a culture 
and society. Though the nature of the crisis varies, hope for the United States is out there, though 
it will take a strong government influence to help solve the crisis. 
History of Opioids 
 
While the United States struggles with an opioid crisis that is killing more than 130 citizens 
every day, China encountered a similar crisis a hundred years earlier (NIH, 2019). Opium was 
introduced into China in the 6th or 7th century by Turk and Arab traders. It was utilized in a 
controlled manner for more than a century to strictly relieve pain and tension. Controlled use 
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exploded into radical usage in the 17th century when tobacco sales from North America escalated 
significantly. Opium was no longer used to relieve pain, but now, like tobacco, it was smoked. 
This increased the number of Chinese who used opium. Because of opium’s addictive quality, soon 
many Chinese were addicted to smoking opium. It became a serious enough problem that the Qing 
dynasty first tried to prohibit the sale and smoking of the drug, with little success. Next to be 
outlawed was the trade and importation of opium into China. Unfortunately, the British East India 
Company had capitalized on the opium cultivation in India and realized they could right their trade 
imbalance with China by selling opium to an addicted China (Pletcher, 2015). China’s ban on 
opium, and Britain’s unwillingness to stop selling opium to China, led to the Opium Wars. The 
first war was between Britain and China lasting from 1839 until 1842, where the Chinese tried to 
prevent Britain from importing opium. The Chinese were unsuccessful. They were forced to 
surrender and sign the Treaty of Nanjing, which gave Britain most-favored-nation status. The 
second Opium War was between Britain and France against China from 1856 until 1860. Again 
China lost and was forced to legalized opium trade (Pletcher, 2019). Eventually in 1907 China was 
finally able to sign a treaty with India called the Ten Years’ Agreement that would allow for the 
reduction in importation of opiates to China with the cessation of opium importation by 1917. It 
wasn’t until the Communists came to power in 1949 that China was able to eradicate opium 
smoking (Pletcher, 2015). 
Opioid Treatment 
 
Buprenorphine is a partial opioid agonist, meaning it binds to the same mu-receptor in the 
nervous system that opioids bind. Because it binds to the same cell receptor sites, it helps relieve 
withdrawal symptoms, as it stimulates similar psychological activity.  At a maintenance dosage, it 
does not induce euphoria like opioids. By binding to the same cell mu receptors as 
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opioids, it prevents the body from binding (and absorbing) the effects of all the opioids a person 
has taken, so the effects of the opioids are diminished. Methadone is a complete opioid agonist, 
and thus will bind with a high affinity to the same mu-receptors as opioids. Methadone, like 
buprenorphine, helps to lessen withdrawal systems without creating the same euphoria as the illicit 
self-administered opioids  (Pike & Usa, 2009). Naloxone, unlike the other two drugs, is a complete 
antagonist, and binds at an even higher affinity to the  mu-receptors, out competing opioids. Due 
to its high affinity, it can cause serious withdrawal effects. It should not be taken until a patient has 
been opioid free for 7-10 days, unless a patient has overdosed on opioids, then Naloxone should be 
administrated, as it will help reverse the binding of opioids to the receptors (SAMHSA, n.d.). 
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Appendix B Hospital Quality Improvement Program 
 
Follow-up treatment after ED visit for Opioid Use Disorder (OUD) 
 
Final 
January 17, 2019 
 
A new hospital quality incentive program will be established based on a modified HEDIS® 
specification of follow up within 7 days for opioid treatment after a visit to the emergency 
department (ED) for opioid use disorder (OUD). Trended performance for this metric would be 
established for each ED using Calendar Year (CY) 2016 and CY 2017 claims data. 
 
The event denominator will be any HealthChoices member seen in the ED for OUD. 
 
The event numerator will be anyone in the denominator seen for OUD treatment within 7 days of 
discharge from the ED. 
 
Each ED will have the opportunity to earn benchmark and incremental improvement incentives 
using CY 2018 as a base year and CY 2019 as the first year to earn a performance incentive. 
The payout structure will be similar to our preventable admissions QIP. Incentive payments will 
be made in 2020. The amount allocated for benchmark and incremental improvement payments 
will be $35 million. 
 
This activity will align with other OUD warm hand off initiatives and OMAP’s focus on pregnant 
women with OUD. The first performance incentives (benchmark and incremental improvement) 
would be paid in October 2020. 
 
Also during 2019, health systems will have the opportunity to earn “process” incentives by 
implementing defined clinical pathways. These pathways will help the health systems get more 
individuals with OUD into treatment and improve the 7 day follow up performance in 2019. 
Health systems may implement all or any of the following four clinical pathways: 
1. ED initiation of buprenorphine with warm hand off to the community; 
2. Direct warm hand off to the community for MAT or abstinence based treatment; 
3. Specialized protocol to address pregnant women with OUD; and 
4. Direct inpatient admission pathway for methadone or observation for buprenorphine 
induction. 
 
The emergency departments of health systems will be awarded a base payment of $25,000 for 
the initial pathway implemented and additional payments for the 2nd, 3rd, and 4th pathways 
implemented as follows: 2nd Pathway - $37,000, 3rd Pathway - $56,000, 4th Pathway - 
$75,000. This would allow a hospital that implements all 4 pathways to receive a payment 
totaling $193,000. Any remaining funds available after the pathway payments are completed will 
be distributed to eligible hospitals based on the proportion of each eligible hospital’s CY2016 
OUD related ED visits divided by the total CY2016 OUD related ED visits for all eligible 
hospitals. A hospital is eligible to receive a remaining funds payment by attesting to and 
implemented at least one pathway. 
 
The amount allocated for clinical pathway payments will be $30 million. Payment will be made 
by July 31, 2019. 
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Pathways Requirements 
1. Each of the pathways will need to be clearly defined in writing by 9/28/18 and verified as 
operational with a minimum number of HealthChoices recipients by 1/17/19. The minimum 
number of HealthChoices recipients is determined by the volume of OUD related ED visits 
that occurred in CY2016: 
a. Tier 1: Low-volume EDs – Hospitals that had less than 20 OUD ED visits must have 
a minimum of 1 HealthChoices recipients. 
b. Tier 2: Standard EDs – Hospitals that had between 20 and 200 OUD ED visits must 
have a minimum of 10 HealthChoices recipients. 
c. Tier 3: High Volume EDs – Hospitals that had more than 200 OUD ED visits must 
have a minimum of 20 HealthChoices recipients. 
2. These care management teams will be focused on warm hand-offs from the ED to inpatient 
admission, observation status, external drug and alcohol providers for all ASAM levels of 
care, and local Centers of Excellence or PACMAT programs. 
a. The care management team is expected to have on-call care management 24-hour 
coverage. 
b. Health systems are expected to train existing ED care management personnel and 
ED providers on appropriate OUD guidelines of care, stigma prevention, SBIRT, and 
MAT waiver prescriber training (physicians, CRNPs, PAs if initiating buprenorphine 
pathway #1). 
3. Health systems will attest in writing to these requirements no later than 11/30/18. 
4. Health systems be actively working towards submitting electronic continuity of care 
documents (CCDs) to the Department for Medicaid recipients seen in the ED with a 
diagnosis of OUD by 7/1/2019. 
 
Historic Data Analysis 
 
Below is an example of trended ED data from 2014 to 2017 for individuals with a diagnosis of 
OUD either within the top 3 or top 9 diagnosis positions on the HealthChoices encounters. The 
table also lists 7 day or 30-day follow-up rates for at least one OUD treatment. 
 
 
 
- 
 
 
 
 
 
 
 
 
Below is a summary of the results of CY 2015 to 2016 modeling for benchmark and incremental 
improvement using the 9 diagnoses and 7day follow-up data. 
 
Hospitals/ED no payment 
  
22% 
Hospitals/ED both   22% 
Hospitals/ED bench only   28% 
Hospitals/ED incremental only   28% 
Hospitals/ED <20 visits 2016 0r 17   15% 
median =>25.0%  
 
 2014  2015 2016 2017* 
  
Recipie nt/ 
Visit 
Received 
a 7 or 30 
Day 
Follow-up 
 
 
Rate 
  
Recipie nt/ 
Visit 
Received a 
7 or 30 
Day Follow 
up 
 
 
Rate 
 
Recipie 
nt/Visit 
Received 
a 7 or 30 
Day 
Follow-up 
 
 
Rate 
 
Recipie 
nt/Visit 
Received 
a 7 or 30 
Day 
Follow-up 
 
 
Rate 
9Dx_30d 12,662 6,649 52.5%  20,838 9,880 47.4% 33,531 14,774 44.1% 33,111 14,641 44.2% 
3Dx_30d 7,542 4,145 55.0%  13,500 6,644 49.2% 24,528 10,971 44.7% 24,354 10,813 44.4% 
              
9Dx_7d 12,662 4,525 35.7%  20,838 6,483 31.1% 33,531 9,367 27.9% 33,111 9,290 28.1% 
3Dx_7d 7,542 2,878 38.2%  13,500 4,344 32.2% 24,528 6,901 28.1% 24,354 6,874 28.2% 
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Appendix C Hospital Quality Improvement Program 
 
Opioid Use Disorder Emergency Department Initiative 
Performance Measure 
 
The Opioid Use Disorder (OUD) for Emergency Department (ED) follow-up reports are 
generated using a Department of Human Services (DHS) modification on the HEDIS© measure 
“Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or 
Dependence (FUA)”. 
 
While the HEDIS© measure is looking at all types of alcohol or other drug (AOD) abuse, the 
DHS modification limits the data included to only Opioid/Opioid Poisoning diagnoses. Also, the 
HEDIS© measure only evaluates the primary (or the first) diagnosis on the claim/encounter. The 
DHS modification includes diagnoses in up to the ninth position. 
 
Each version applies a continuous enrollment limitation (from the date of the ED visit through 30 
days after the ED visit - 31 days total) to the eligible denominator population. The DHS 
modification is limited to Medical Assistance recipients enrolled in a Medicaid MCO participating 
in the Physical Health HealthChoices program during that eligibility period. 
 
The HEDIS© measure is very prescriptive and limited as to what is included as a follow-up and 
includes follow ups in both 7 and 30 days. The DHS modification includes all ED visits (with or 
without admittance) that received treatment, as identified by DHS, within 7 days of their OUD 
related ED visit. DHS will also include admissions that meet the modified inpatient criteria are 
included in the numerator. DHS will not consider another ED visit as an acceptable follow-up 
within 7 days. 
 
This measure is being used to evaluate each ED visited by the recipients separately. If there 
were multiple ED visits to the same ED within 7 days and all visits include OUD related 
diagnosis in up to the ninth position, then DHS considers the first date of service to be “anchor 
date” or date to begin the evaluation. When a recipient has OUD related ED visits to multiple 
EDs within the 7 day follow-up period, DHS will evaluate each ED separately. 
 
 
 
 
Updated April 30, 2019 
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Appendix D Opioid Use Disorder Team Charter 
 
 
 
Team Lead 
 
Title VP of Quality & Safety 
Team 
Leadership 
   Title  
ED Medical Director and Institute 
Chair 
Team Sponsor    Title System CMO/CQO 
Start Date August, 2018 Expected Complete 
Date 
7 months (March 31, 2019) 
Project Name Follow Up Treatment after ED visit for 
Opioid Use Disorder 
PI Resource Process Improvement/Process Engineering 
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Background 
[pilot results] 
 
 
Opioid Use Disorder Team Charter 
In 2013, 16,235 Americans died from prescription opioid misuse — four times more than in the entire 
previous decade and greater than the number of deaths that year from heroin, cocaine, and 
benzodiazepines combined. From 2000 to 2009, the number of opioid prescriptions increased by 68 
percent, reaching 202 million prescriptions. Opioids — both prescription painkillers and heroin — are 
the primary drug associated with drug overdoses; in 2014, opioids were involved in 61 percent of all 
drug overdose deaths. From 2013 to 2014, there was a 9 percent increase in deaths attributed to 
overdose of commonly prescribed opioid pain relievers. 
 
In 2010, hydrocodone/ acetaminophen was the most commonly prescribed drug in the United States, 
with 131.2 million prescriptions; the US uses 99 percent of the world’s supply. 
 
One of the most significant drivers of the opioid crisis is the lack of a system-level approach across 
communities. 
 
The picture below shows the number of painkiller prescriptions by state. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reference: Martin L, Laderman M, Hyatt J, Krueger J. Addressing the Opioid Crisis in the United States. IHI Innovation 
Report. Cambridge, Massachusetts: Institute for Healthcare Improvement; April 2016. (Available at ihi.org) 
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Opioid Use Disorder Team Charter 
 
 In July, 2017 the President’s Commission on Combating Drug Addiction and the Opioid Crisis issued 
a draft interim report to the President which included several recommendations. The recommendations 
were to inform state activity related to opioids. 
Recently, DHS announced (through HAP) a new hospital quality incentive program that would allow 
hospitals the opportunity to earn incentive payments for implementing specific clinical pathways that 
individuals can use following treatment in an Emergency Department (ED) setting for opioid use 
disorder (OUD). The goal of the pathways is to avoid the need for repeat treatment in an ED setting by 
helping individuals with OUD receive other treatment within 7-days of receiving care in an ED. 
The new measures contain two components: 
1. Component #1—Process Incentive: Implementation of defined clinical pathways (Year 1) 
2. Component #2—“Outcome” Incentive: Modified Healthcare Effectiveness Data 
Information Set specification of follow-up within seven days for opioid treatment after a visit 
to the emergency department for OUD (Year 2) 
Component #1—Process Incentive: Health systems may implement all or any of the following four 
clinical pathways: 
3. ED initiation of buprenorphine with warm hand off to the community; 
4. Direct warm hand off to the community for MAT or abstinence based treatment; 
5. Specialized protocol to address pregnant women with OUD; and 
6. Direct inpatient admission pathway for methadone or observation for buprenorphine 
induction. 
Hospitals must also have: 
7. Care management teams focused on warm hand-offs from the ED to inpatient admission, 
observation status, external drug and alcohol providers for all American Society of Addiction 
Measures (ASAM) levels of care, and local Centers of Excellence or Pennsylvania 
Coordinated Medication-Assisted Treatment (PACMAT) programs are in place. 
8. On-call care management available 24-hours a day. 
a. ED care management personnel and ED providers have been trained on the clinical 
pathways. 
9. Attest to having begun to work towards submitting electronic continuity of care documents 
(Admission, Discharge, Transfer forms) to DHS for Medicaid recipients seen in the ED with a 
diagnosis of OUD by 7/1/2019. 
Below is a historical data by HSX facility for all included diagnoses and by Health Choice recipient. 
Table 1: HSX Opioid Use Data 2016-2018 
 
All Diagnosis 
   
  
2016 2017 2018 
 
 All Patients 718 675 587 Tier 3 
X4 
Health Choice 287 260 118  
 All Patients 221 245 124 Tier 2 
X1 Health Choice 
93 103 39  
 
All Patients 
77 94 51 Tier 2 
X2 Health Choice 
24 32 7  
Tier 3   
346 370 223 
X5 All Patients  
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Opioid Use Disorder Team Charter 
 
   Health Choice 143 132 73  
Tier 3  
 
X6 
All Patients 253 257 203 
Health Choice 8 33 59 
 
   
 
X7 
All Patients 377 454 406 Tier 3 
 
 
Tier 2 
Health Choice 30 35 79 
 
 
X3 
All Patients 220 184 125 
Health Choice 71 65 30 
Strategic 
Objective (Core 
Behavior) 
advanced by this 
PI opportunity 
• Customers First 
• Purposeful Execution 
• Trust Working Together 
 
Connect to Office Priorities (from Office of the CMO priorities). 
FOCUS AIM for Component 1: Develop/Define all four opioid use clinical pathways for each HSX facility 
by November 30, 2018. 
AIM for Component 2: Achieve 90% compliance or above with 7 and 30 day follow up for Opioid 
patients visiting ED from January 2019-December 2019. 
 
Milestones #1: Before November 30th, 2018-- Stage 1: Defining and Developing; Stage 2: Attestation 
 
Milestone #2: Before January 17th, 2019-- Stage 3: Operational Implementation 
Milestone #3: March 31st, 2019-- Stage 4: Reviewing and Sustaining 
Outstanding Topics to Discuss: 
1. Education Needs -What? -Who? 
2. EPIC Needs 
3. Data Needs 
4. Submission of ADT feeds 
Find and define 
the improvement 
opportunity. 
 
1. What are 
you 
trying to 
accomplish 
(AIM 
statement)? 
2. How will 
you know that an 
improvement 
occurred 
(Measure(s))? 
3. What 
changes 
(interventions) 
will be made to 
result in 
improvements? 
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Opioid Use Disorder Team Charter 
 
Organize 
Organize a team 
who understands 
the process (List 
team members 
and their roles). 
Identify the Team Members needed for each clinical pathway: RACI? 
Local quality expert 
Data expert 
Regulatory expert 
Strategy expert 
Quality & Safety expert 
PI/Process Engineering expert 
Case Management expert 
Data expert 
Nursing/Education expert 
Local quality expert 
Clinical/Content expert 
EPIC expert 
Coding expert 
Clarify Clarify 
current 
knowledge of the 
process. 
Identify the current state of the pathways per each facility (see clinical pathways in invite) 
Understand 
Understand the 
causes of the 
process variation. 
Identify where there are gaps (based on future state process map) 
Specific 
Select a specific 
process to 
improve and test. 
PDSA after selecting an improvement. 
 
Delineate between process improvement and process creation. 
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Appendix E Opioid Learning Action Network 
 
 
 Hospital Association of Pennsylvania’s (HAP) Opioid Learning Action Network (LAN)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
https://haponlinecontent.azureedge.net/resourcelibrary/HAP-Opioid-LAN-May-2019.pdf 
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